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Background
First reported in 1892 in Japan by Kure,1,2 paroxysmal kinesigenic 
dyskinesia (PKD; OMIM # 128200) is a rare movement disorder, with 
a prevalence of  about 1:150,000 individuals.2 It has an autosomal dom-
inant inheritance, and with its variable expression and incomplete pen-
etrance, the above figure may underestimate the true prevalence.2,3 The 
main clinical features are brief  dyskinesias upon initiation of  move-
ment (Table 1).2–4 There is a conspicuous response to carbamazepine 
and phenytoin, in dosages much lower than required for seizure 
disorders.2–4
The PRRT2 gene is located on chromosome 16, was first identified in 
the Chinese population and codes for a member of  a central nervous 
system transmembrane protein family.5,6 PRRT2 gene mutations have 
also been implicated in other paroxysmal movement disorders such as 
infantile convulsions, benign familial infantile epilepsy, and infantile 
 convulsions with choreoathetosis syndrome.2,3 PKD has been described 
all over the world including African-American patients,7,8 but not in 
Africa itself. This first genetically confirmed PKD from Africa adds to the 
ubiquitous nature of  the predominant PRRT2 frameshift mutation,3 
which was also found in this patient. Knowledge of  its salient clinical 
features (Table 1) lends itself  to recognition regardless of  a low-resource 
setting.
Case report
A 12-year-old male reported to Kilimanjaro Christian Medical Centre 
in Moshi, Northern Tanzania, with complaints of  abdominal fullness 
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Abstract
Background:  Paroxysmal kinesigenic dyskinesia (PKD) is a movement disorder, with an excellent response to carbamazepine treatment. It has been described in 
various populations, but not yet in an African population.
Case report:  In a patient who reported to clinic with side effects of  carbamazepine, PRRT2 gene screening was performed based on a clinical history compatible 
with PKD. A common PRRT2 mutation was identified in this patient, hereby the first genetically confirmed PRRT2-associated PKD in Africa.
Discussion:  Reporting genetic confirmation of  an unusual movement disorder from an equally unusual location shows the wide geographical distribution of  
PRRT2-associated disease. It also illustrates recognizability of  this treatable disorder where the easiest accessible diagnostic tool is neurological history and 
examination.
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after his daily medication intake. He was the second out of  three chil-
dren from nonconsanguineous parents. An elder teenage sister and baby 
brother had no symptoms at the time of  this study. There was no medi-
cal history or family history of  neurological disorders except for per-
sistent mild stuttering in the father. The patient had been using 
low-dosage carbamazepine (100 mg twice daily) since 2 years before 
presenting to our hospital. Side effects were abdominal fullness, nausea, 
and occasional chest pain. At the age of  6 years, he received the diagno-
sis of  a functional movement disorder, followed by the diagnosis of  com-
plex partial epilepsy, for which carbamazepine was prescribed. This 
caused symptoms to disappear.
The symptoms consisted of  sudden, painless twisting movement of  
arms, trunk, face, tongue, and, to lesser extent, legs. It would occur 
almost every time he initiated movement, lasting 10–20 seconds. His 
tongue twisted within his mouth so that he could not talk or swallow, 
and his involuntary leg movements made him fall. Loss of  consciousness 
never occurred. Symptoms completely resolved with carbamazepine 
use, but when his medication ran out all would recur within 2 days. 
A proton pump inhibitor had relieved the carbamazepine-related 
abdominal complaints so that carbamazepine benefits still outweighed 
the burden of  side effects.
Physical examination revealed no dysmorphisms. Skin, muscle 
bulk, joints, and chest auscultation was normal. Neurological exam-
ination in the patient, father, and sister was also normal, with no 
 features of  myotonia or provocation by exercise or sudden movement. 
Magnetic resonance imaging of  the brain, electrocardiogram, and 
blood and cerebrospinal fluid analysis (CSF) were unremarkable, 
with normal blood glucose of  6.0 mmol/L and CSF glucose of  
3.6 mmol/L. Based on history, dramatic medication response, and 
the normal interictal physical examination (Table 1), the clinical diag-
nosis was PKD. The PRRT2 gene was most likely to explain this clin-
ical phenotype.3
Written informed consent in English and kiSwahili was obtained 
from the patient himself, and from the next-of-kin, his accompanying 
father. Venous blood was sampled and sent to the Genome Diagnostics 
Nijmegen of  Radboud University Medical Center, Nijmegen, The 
Netherlands, for PRRT2 mutation analysis. Genetic counseling before 
and after test results was done in the presence of  patient and his 
father, in English and kiSwahili, and information was provided in 
written form.
DNA sequence analysis of  the PRRT2 gene revealed a heterozygous 
pathogenic frameshift mutation c.649dup (p.(Arg217fs)) (NM_145239.2), 
confirming the diagnosis of  PKD. This frameshift mutation at a muta-
tional hotspot gives rise to a premature stop codon. It has been reported 
to make up 78.5% of  all PKD-associated PRRT2 mutations.2
Discussion
A first genetic confirmation from a certain geographical region is not 
a scientific novelty, and the same PRRT2 frameshift mutation was 
already described in an African-American family in the United States.8 
Furthermore, this patient’s serendipitous treatment with carbamazepine 
is not exceptional because it is a locally available and affordable drug, 
used for various epilepsy and mental health symptoms and signs. The 
diagnostic delay in this case did not lead to treatment delay. However, 
neurology and genetics facilities are still unavailable in most of  Africa,9,10 
and this observation stresses the value of  movement disorders education 
in low-resource areas.
There is variation in genetic and phenotypic expression. PRRT2 is 
implicated in PKD and other paroxysmal movement disorders, seizure 
disorders, and intellectual impairment,2,3 and other genes are involved 
in non-PRRT2 PKD. As penetrance is incomplete2,3 and parents have 
declined further testing, it is not known whether the PRRT2 mutation in 
our patient is de novo. The patient’s father had a mild, yet persistent stut-
ter. It remains speculative whether this could be a mild phenotype with 
kinesigenic dysfunction of  the oropharyngeal musculature alone. 
Screening for PRRT2 mutation in a cohort of  stammer patients has not 
been performed, although other genetic associations with stammering 
are there.11
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